fda semaglutide news The approved a pill version of the GLP-1 receptor agonist (Wegovy), making it the first oral GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday. The once-daily 25 Novo Nordisk, FDA Score Win

Image Credit: AtlasStudio / Shutterstock A recent editorial published in the journal Expert Opinion on Pharmacotherapy discussed that glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) may potentially transform health outcomes for individuals with serious mental illnesses (SMIs)

Contact Orderly Meds customer support immediately

GLP-1 medications are typically recommended for adults who meet specific Body Mass Index (BMI) criteria: Individuals with a BMI of 30 kg/m or greater (classified as obesity)

Their peptide structure closely mimics the natural GLP-1 hormone, giving them high receptor binding affinity and predictable pharmacokinetics